BMO Capital raised the firm’s price target on MacroGenics to $24 from $18 and keeps an Outperform rating on the shares. The company provided a business update, disclosing the submission of an abstract to present preliminary Phase 2 TAMARACK data for vobramitamab duocarmazine in mCRPC at ASCO in June, and the firm is citing its higher conviction for MacroGenics in prostate cancer ahead of ASCO and second-half updates, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MGNX:
- MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
- MacroGenics price target raised to $24 from $12 at BTIG
- MacroGenics to Participate in Upcoming Investor Conferences
- MacroGenics price target raised to $23 from $12 at Barclays
- MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
